Demonstration of Clinical Comparability of the Biosimilar Filgrastim to Neupogen, in Terms of Safety and Efficacy, in Healthy Volunteers and Patients Receiving Myelosuppressive Chemotherapy

Bernd Jilma,1 Agnieszka Jagiello-Gruszfeld,2 Piotr Tomczak,3 Himanshu Gadgil,4 Grzegorz Orlik,5 Kalpna Desai,6 Tina Catalano6 and Jason Dowd6

1. Professor, Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; 2. Oncologist, The Institute of Maria Skłodowska-Curie Cancer Center and Institute, Warsaw, Poland; 3. Head of Chemotherapy Department, Clinic of Oncology, Poznan University of Medical Sciences, Poznan, Poland; 4. Intas Pharmaceuticals Limited, Gujarat, India; 5. Accord Healthcare, Warsaw, Poland; 6. Apotex Inc., Toronto, Ontario, Canada

The authors and publisher would like to make the following corrections to this article:

In the sub-section Phase III, KWI-300-104 on page 113, the percentage of adverse events described as severe should read 8.14 %.

The corrected statement reads:

Most AEs were described as mild in severity (748 events, 61.51 %). AEs were described as moderate in 368 (30.26 %), severe in 99 (8.14 %) and life threatening in one (0.08 %) case.

In Figure 4 the vertical axis should read "ANC (G/l)" instead of "ANC (mg/l)".